Sign up for a free trial now

Login
Subscribe
Take a FREE Trial

About Us
Contact us
RSS

20 May 2013

Search

The Pharma Letter

Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe

Acrux Articles

US FDA approves Axiron, first testosterone replacement from Eli Lilly and Acrux

25 November 2010

Vivus returns rights to develop Luramist to Acrux

1 April 2010

Showing 1-2 of 2 articles

Go to beginning

Previous

1

Next

Go to end

Hot Topics
Most Read

Bristol-Myers' data on Yervoy and nivolumab causes a stir
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
Encouraging results with Sangamo's SB-728-T in HIV treatment
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
New study shows UCB's Neupro reduces NSBP in RLS patient

Bristol-Myers' data on Yervoy and nivolumab causes a stir
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
Encouraging results with Sangamo's SB-728-T in HIV treatment
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
New study shows UCB's Neupro reduces NSBP in RLS patient

© 2013 thepharmaletter.com

Home
RSS
About Us
Subscribe
Terms and Conditions
Article Archive

Site powered by WORKSsitebuilder CMS